Crescent Biopharma (CBIO) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Crescent Biopharma

NasdaqCM•Healthcare•Biotechnology

$20.88+0.48(0.02%)Market closed

Market Cap

$515.69M

P/S

43.4x

P/B

3.2x

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.

How this company scores

AverageMetricSide Score: 41/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Cash & Earnings Quality (6/25).

Profitability8/25

Growth12/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Long cash runwayInterest easily coveredNet cash positionNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 43.4x5y range 11.1x – 1959499.9x

Currently below its 14-quarter median.

P/B · 3.2x5y range 0.4x – 677.8x

Currently below its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $515.69M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $11.88M
Q. Revenue: $0
TTM EBITDA: $-180.05M
TTM Op. Income: $-180.30M
Q. Op. Income: $-26.36M
TTM Net Income: $-177.93M
Q. Net Income: $-24.84M
EPS: $-0.74
Shares Out.: $30.53M

$11.88M in TTM revenue grew from zero YoY, reaching $0 last quarter. TTM EBITDA of $-180.05M and TTM operating income of $-180.30M show growth is flowing through to the bottom line. However, net income is negative at $177.93M — growth is not yet reaching the bottom line.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: N/A
Op. Margin: -2636400000.0%
Net Margin: -2483700000.0%

Op. margin of -2636400000.0% is down 533400000.0% YoY — costs are rising relative to revenue. Net margin at -2483700000.0% Across the last 8 quarters, operating margin has fallen for 2 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 43.4x
P/B Ratio: 3.2x

P/S of 43.4x and P/B of 3.2x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $182.76M
Cash: $171.59M
Long-Term Debt: N/A
Book Value: $163.25M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-19.46M
TTM Free Cash Flow: $-73.62M
FCF Margin: -619.5%
FCF / Net Income: 0.4

TTM FCF of $-73.62M on $-19.46M in operating cash flow. The FCF / Net Income ratio of 0.4x means cash covers only part of net income — earnings quality needs attention. Over the past year, free cash flow is down 88% — an improving trend.